Inborn Errors of Metabolism
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Hyperammonemia in Review: Pathophysiology, Diagnosis, and Treatment
Pediatr Nephrol DOI 10.1007/s00467-011-1838-5 EDUCATIONAL REVIEW Hyperammonemia in review: pathophysiology, diagnosis, and treatment Ari Auron & Patrick D. Brophy Received: 23 September 2010 /Revised: 9 January 2011 /Accepted: 12 January 2011 # IPNA 2011 Abstract Ammonia is an important source of nitrogen and is the breakdown and catabolism of dietary and bodily proteins, required for amino acid synthesis. It is also necessary for respectively. In healthy individuals, amino acids that are not normal acid-base balance. When present in high concentra- needed for protein synthesis are metabolized in various tions, ammonia is toxic. Endogenous ammonia intoxication chemical pathways, with the rest of the nitrogen waste being can occur when there is impaired capacity of the body to converted to urea. Ammonia is important for normal animal excrete nitrogenous waste, as seen with congenital enzymatic acid-base balance. During exercise, ammonia is produced in deficiencies. A variety of environmental causes and medica- skeletal muscle from deamination of adenosine monophos- tions may also lead to ammonia toxicity. Hyperammonemia phate and amino acid catabolism. In the brain, the latter refers to a clinical condition associated with elevated processes plus the activity of glutamate dehydrogenase ammonia levels manifested by a variety of symptoms and mediate ammonia production. After formation of ammonium signs, including significant central nervous system (CNS) from glutamine, α-ketoglutarate, a byproduct, may be abnormalities. Appropriate and timely management requires a degraded to produce two molecules of bicarbonate, which solid understanding of the fundamental pathophysiology, are then available to buffer acids produced by dietary sources. differential diagnosis, and treatment approaches available. -
Clinical Spectrum of Glycine Encephalopathy in Indian Children
Clinical Spectrum of Glycine Encephalopathy in Indian children Anil B. Jalan *, Nandan Yardi ** NIRMAN, 203, Nirman Vyapar Kendra, Sector 17, Vashi – Navi-Mumbai, India – 400 705 * Chief Scientific Research Officer (Bio – chemical Genetics) ** Paediatric Neurologist an Epileptologist, Pune. Introduction: NKH is generally considered to be a rare disease, but relatively higher incidences have been reported in Northern Finland, British Columbia and Israel (1,2). Non Ketotic Hyperglycinemia, also known as Glycine Encephalopathy, is an Autosomal recessive disorder of Glycine metabolism caused by a defect in the Glycine cleavage enzyme complex (GCS). GCS is a complex of four proteins and coded on 4 different chromosomes. 1. P – Protein ( Pyridoxal Phosphate containing glycine Decarboxylase, GLDC) -> 80 % cases, [ MIM no. 238300 ] , 2. H – Protein (Lipoic acid containing) – Rare, [MIM no. 238310], 3. T – Protein ( Tetrahydrofolate requiring aminomethyltranferase AMT ) – 15 % cases [ MIM no. 238330], 4. L – Protein (Lipoamide dehydrogenase) – MSUD like picture [MIM no. 238331] (1). In classical NKH, levels of CSF – glycine and the ratio of CSF / Plasma glycine are very high (1). Classically, NKH presents in the early neonatal period with progressive lethargy, hypotonia, myoclonic jerks, hiccups, and apnea, usually leading to total unresponsiveness, coma, and death unless the patient is supported through this stage with mechanical ventilation. Survivors almost invariably display profound neurological disability and intractable seizures. In a minority of NKH cases the presentation is atypical with a later onset and features including seizures, developmental delay and / or regression, hyperactivity, spastic diplegia, spino – cerebeller degeneration, optic atrophy, vertical gaze palsy, ataxia, chorea, and pulmonary hypertension. Atypical cases are more likely to have milder elevations of glycine concentrations (2). -
16. Questions and Answers
16. Questions and Answers 1. Which of the following is not associated with esophageal webs? A. Plummer-Vinson syndrome B. Epidermolysis bullosa C. Lupus D. Psoriasis E. Stevens-Johnson syndrome 2. An 11 year old boy complains that occasionally a bite of hotdog “gives mild pressing pain in his chest” and that “it takes a while before he can take another bite.” If it happens again, he discards the hotdog but sometimes he can finish it. The most helpful diagnostic information would come from A. Family history of Schatzki rings B. Eosinophil counts C. UGI D. Time-phased MRI E. Technetium 99 salivagram 3. 12 year old boy previously healthy with one-month history of difficulty swallowing both solid and liquids. He sometimes complains food is getting stuck in his retrosternal area after swallowing. His weight decreased approximately 5% from last year. He denies vomiting, choking, gagging, drooling, pain during swallowing or retrosternal pain. His physical examination is normal. What would be the appropriate next investigation to perform in this patient? A. Upper Endoscopy B. Upper GI contrast study C. Esophageal manometry D. Modified Barium Swallow (MBS) E. Direct laryngoscopy 4. A 12 year old male presents to the ER after a recent episode of emesis. The parents are concerned because undigested food 3 days old was in his vomit. He admits to a sensation of food and liquids “sticking” in his chest for the past 4 months, as he points to the upper middle chest. Parents relate a 10 lb (4.5 Kg) weight loss over the past 3 months. -
Inherited Metabolic Disease
Inherited metabolic disease Dr Neil W Hopper SRH Areas for discussion • Introduction to IEMs • Presentation • Initial treatment and investigation of IEMs • Hypoglycaemia • Hyperammonaemia • Other presentations • Management of intercurrent illness • Chronic management Inherited Metabolic Diseases • Result from a block to an essential pathway in the body's metabolism. • Huge number of conditions • All rare – very rare (except for one – 1:500) • Presentation can be non-specific so index of suspicion important • Mostly AR inheritance – ask about consanguinity Incidence (W. Midlands) • Amino acid disorders (excluding phenylketonuria) — 18.7 per 100,000 • Phenylketonuria — 8.1 per 100,000 • Organic acidemias — 12.6 per 100,000 • Urea cycle diseases — 4.5 per 100,000 • Glycogen storage diseases — 6.8 per 100,000 • Lysosomal storage diseases — 19.3 per 100,000 • Peroxisomal disorders — 7.4 per 100,000 • Mitochondrial diseases — 20.3 per 100,000 Pathophysiological classification • Disorders that result in toxic accumulation – Disorders of protein metabolism (eg, amino acidopathies, organic acidopathies, urea cycle defects) – Disorders of carbohydrate intolerance – Lysosomal storage disorders • Disorders of energy production, utilization – Fatty acid oxidation defects – Disorders of carbohydrate utilization, production (ie, glycogen storage disorders, disorders of gluconeogenesis and glycogenolysis) – Mitochondrial disorders – Peroxisomal disorders IMD presentations • ? IMD presentations • Screening – MCAD, PKU • Progressive unexplained neonatal -
Summary Current Practices Report
18/10/2011 EU Tender “Evaluation of population newborn screening practices for rare disorders in Member States of the European Union” Short Executive Summary of the Report on the practices of newborn screening for rare disorders implemented in Member States of the European Union, Candidate, Potential Candidate and EFTA Countries Authors: Peter Burgard1, Martina Cornel2, Francesco Di Filippo4, Gisela Haege1, Georg F. Hoffmann1, Martin Lindner1, J. Gerard Loeber3, Tessel Rigter2, Kathrin Rupp1, 4 Domenica Taruscio4,Luciano Vittozzi , Stephanie Weinreich2 1 Department of Pediatrics , University Hospital - Heidelberg (DE) 2 VU University Medical Centre - Amsterdam (NL) 3 RIVM - Bilthoven (NL) 4 National Centre for Rare Diseases - Rome (IT) The opinions expressed in this document are those of the Contractor only and do not represent the official position of the Executive Agency for Health and Consumers. This work is funded by the European Union with a grant of Euro 399755 (Contract number 2009 62 06 of the Executive Agency for Health and Consumers) 1 18/10/2011 Abbreviations 3hmg 3-Hydroxy-3-methylglutaric aciduria 3mcc 3-Methylcrotonyl-CoA carboxylase deficiency/3-Methylglutacon aciduria/2-methyl-3-OH- butyric aciduria AAD Disorders of amino acid metabolism arg Argininemia asa Argininosuccinic aciduria bio Biotinidase deficiency bkt Beta-ketothiolase deficiency btha S, beta 0-thalassemia cah Congenital adrenal hyperplasia cf Cystic fibrosis ch Primary congenital hypothyroidism citI Citrullinemia type I citII Citrullinemia type II cpt I Carnitin -
Argininosuccinate Lyase Deficiency
©American College of Medical Genetics and Genomics GENETEST REVIEW Argininosuccinate lyase deficiency Sandesh C.S. Nagamani, MD1, Ayelet Erez, MD, PhD1 and Brendan Lee, MD, PhD1,2 The urea cycle consists of six consecutive enzymatic reactions that citrulline together with elevated argininosuccinic acid in the plasma convert waste nitrogen into urea. Deficiencies of any of these enzymes or urine. Molecular genetic testing of ASL and assay of ASL enzyme of the cycle result in urea cycle disorders (UCDs), a group of inborn activity are helpful when the biochemical findings are equivocal. errors of hepatic metabolism that often result in life-threatening However, there is no correlation between the genotype or enzyme hyperammonemia. Argininosuccinate lyase (ASL) catalyzes the activity and clinical outcome. Treatment of acute metabolic decom- fourth reaction in this cycle, resulting in the breakdown of arginino- pensations with hyperammonemia involves discontinuing oral pro- succinic acid to arginine and fumarate. ASL deficiency (ASLD) is the tein intake, supplementing oral intake with intravenous lipids and/ second most common UCD, with a prevalence of ~1 in 70,000 live or glucose, and use of intravenous arginine and nitrogen-scavenging births. ASLD can manifest as either a severe neonatal-onset form therapy. Dietary restriction of protein and dietary supplementation with hyperammonemia within the first few days after birth or as a with arginine are the mainstays in long-term management. Ortho- late-onset form with episodic hyperammonemia and/or long-term topic liver transplantation (OLT) is best considered only in patients complications that include liver dysfunction, neurocognitive deficits, with recurrent hyperammonemia or metabolic decompensations and hypertension. -
What Disorders Are Screened for by the Newborn Screen?
What disorders are screened for by the newborn screen? Endocrine Disorders The endocrine system is important to regulate the hormones in our bodies. Hormones are special signals sent to various parts of the body. They control many things such as growth and development. The goal of newborn screening is to identify these babies early so that treatment can be started to keep them healthy. To learn more about these specific disorders please click on the name of the disorder below: English: Congenital Adrenal Hyperplasia Esapnol Hiperplasia Suprarrenal Congenital - - http://www.newbornscreening.info/Parents/otherdisorders/CAH.html - http://www.newbornscreening.info/spanish/parent/Other_disorder/CAH.html - Congenital Hypothyroidism (Hipotiroidismo Congénito) - http://www.newbornscreening.info/Parents/otherdisorders/CH.html - http://www.newbornscreening.info/spanish/parent/Other_disorder/CH.html Hematologic Conditions Hemoglobin is a special part of our red blood cells. It is important for carrying oxygen to the parts of the body where it is needed. When people have problems with their hemoglobin they can have intense pain, and they often get sick more than other children. Over time, the lack of oxygen to the body can cause damage to the organs. The goal of newborn screening is to identify babies with these conditions so that they can get early treatment to help keep them healthy. To learn more about these specific disorders click here (XXX). - Sickle Cell Anemia (Anemia de Célula Falciforme) - http://www.newbornscreening.info/Parents/otherdisorders/SCD.html - http://www.newbornscreening.info/spanish/parent/Other_disorder/SCD.html - SC Disease (See Previous Link) - Sickle Beta Thalassemia (See Previous Link) Enzyme Deficiencies Enzymes are special proteins in our body that allow for chemical reactions to take place. -
Fatal Propionic Acidemia: a Challenging Diagnosis
Issue: Ir Med J; Vol 112; No. 7; P980 Fatal Propionic Acidemia: A Challenging Diagnosis A. Fulmali, N. Goggin 1. Department of Paediatrics, NDDH, Barnstaple, UK 2. Department of Paediatrics, UHW, Waterford, Ireland Dear Sir, We present a two days old neonate with severe form of propionic acidemia with lethal outcome. Propionic acidemia is an AR disorder, presents in the early neonatal period with progressive encephalopathy and death can occur quickly. A term neonate admitted to NICU on day 2 with poor feeding, lethargy and dehydration. Parents are non- consanguineous and there was no significant family history. Prenatal care had been excellent. Delivery had been uneventful. No resuscitation required with good APGAR scores. Baby had poor suck, lethargy, hypotonia and had lost about 13% of the birth weight. Initial investigations showed hypoglycemia (2.3mmol/L), uremia (8.3mmol/L), hypernatremia (149 mmol/L), severe metabolic acidosis (pH 7.24, HCO3 9.5, BE -18.9) with high anion gap (41) and ketonuria (4+). Hematologic parameters, inflammatory markers and CSF examination were unremarkable. Baby received initial fluid resuscitation and commenced on IV antibiotics. Generalised seizures became eminent at 70 hours of age. Loading doses of phenobarbitone and phenytoin were given. Hepatomegaly of 4cm was spotted on day 4 of life. Very soon baby became encephalopathic requiring invasive ventilation. At this stage clinical features were concerning for metabolic disorder and hence was transferred to tertiary care centre where further investigations showed high ammonia level (1178 μg/dl) and urinary organic acids were suggestive of propionic acidemia. Specific treatment for hyperammonemia and propionic acidemia was started. -
Overview of Newborn Screening for Organic Acidemias – for Parents
Overview of Newborn Screening for Organic Acidemias – For Parents What is newborn screening? What organic acidemias are on Indiana’s newborn screen? Before babies go home from the nursery, they have a Indiana’s newborn screen tests for several organic small amount of blood taken from their heel to test for acidemias. Some of the organic acidemias on a group of conditions, including organic acidemias. Indi ana’s newborn screen are: Babies who screen positive for an organic acidemia 3-Methylcrotonyl-CoA carboxylase need follow-up tests done to confirm they have the deficiency (also called 3-MCC deficiency) condition. Not all babies with a positive newborn Glutaric acidemia, type I screen will have an organic acidemia. Isovaleric acidemia Methylmalonic acidemia What are organic acidemias? Multiple-CoA carboxylase deficiency Propionic acidemia Organic acidemias are conditions that occur when a person’s body is not able to use protein to make What are the symptoms of organic acidemias? energy. Normally, when we eat, our bodies digest (or break down) food into certain proteins. Those Every child with an organic acidemia is different. proteins are used by our bodies to make energy. Most babies with organic acidemias will look normal Enzymes (special proteins that help our bodies at birth. Symptoms of organic acidemias can appear perform chemical reactions) usually help our bodies shortly after birth, or they may show up later in break down food and create energy. infancy or childhood. Common symptoms of organic A person with an organic acidemia is missing at least acidemias include weakness, vomiting, low blood one enzyme, or his/her enzymes do not work sugar, hypotonia (weak muscles), spasticity (muscle correctly. -
Transient Acquired Fanconi Syndrome with Unusual and Rare Aetiologies: a Case Study of Two Dogs
Veterinarni Medicina, 65, 2020 (01): 41–47 Case Report https://doi.org/10.17221/103/2019-VETMED Transient acquired Fanconi syndrome with unusual and rare aetiologies: A case study of two dogs Ju-Yong Park1, Ji-Hwan Park1, Hyun-Jung Han2, Jung-Hyun Kim3* 1Department of Veterinary Internal Medicine, Veterinary Medical Teaching Hospital, Konkuk University, Seoul, Republic of Korea 2Department of Veterinary Emergency, College of Veterinary Medicine, Konkuk University, Seoul, Republic of Korea 3Department of Veterinary Internal Medicine, College of Veterinary Medicine, Konkuk University, Seoul, Republic of Korea *Corresponding author: [email protected] Ju-Yong Park and Ji-Hwan Park contributed equally to this work Citation: Park JY, Park JH, Han HJ, Kim JH (2020): Transient acquired Fanconi syndrome with unusual and rare aetiolo- gies: A case study of two dogs. Vet Med-Czech 65, 41–47. Abstract: The acquired form of Fanconi syndrome is seldom identified in dogs; those cases that have been reported have been secondary to hepatic copper toxicosis, primary hypoparathyroidism, ingestion of chicken jerky treats, exposure to ethylene glycol, or gentamicin toxicity. However, to the best of our knowledge, there have been no reports of acquired Fanconi syndrome secondary to Babesia infection or ingestion of cosmetics in dogs. We here report on two dogs presented with a history of marked polyuria, polydipsia, and lethargy. Laboratory examina- tions showed glucosuria with normoglycaemia and severe urinary loss of amino acids. One dog was infected with Babesia gibsoni and the other dog had a history of cosmetics ingestion. The first dog received treatment for Babesia infection and the second dog received aggressive care to correct metabolic acidosis, electrolyte imbalances, and other add-on deficiencies. -
Amino Acids (Urine)
Amino Acids (Urine) A profile of amino acids is provided: alanine, -amino butyric acid, arginine, asparagine, aspartic acid, carnosine, citrulline, cystine, glutamic acid, glutamine, glycine, histidine, homocystine, hydroxylysine, isoleucine, leucine, Description lysine, methionine, 1-methyl histidine, 3-methyl histidine, ornithine, phenylalanine, phosphoethanolamine, proline, sarcosine, serine, taurine, threonine, tyrosine, tryptophan, valine. In general, urine is useful when investigating a disorder of renal transport particularly with a positive urine nitroprusside test eg for cystinuria and homocystinuria, nephrolithiasis and or the Fanconi syndrome. Other Indication reasons maybe selective metabolic screening, hyperammonaemia, suspected aminoacidopathy, suspected disorder of energy metabolism, epileptic encephalopathy, control of protein restricted diet. Functions of amino acids include the basic structural units of proteins, metabolic intermediates and neurotransmission. Over 95% of the amino acid load filtered from the blood at the renal glomerulus is normally reabsorbed in the proximal Additional Info renal tubules by saturable transport systems. The term ‘aminoaciduria’ is used when more than 5% of the filtered load is detected in the urine. In normal individuals, aminoaciduria is transient and is associated with protein intake in excess of amino acid requirements. Concurrent Tests Plasma amino acids Dietary Requirements N/A Values depend on metabolic state. Cystinuria: Increased urinary cystine, lysine, arginine and ornithine. Interpretation Homocystinuria: Increased urinary homocysteine and methionine. Fanconi syndrome: Generalised increase in urinary amino acid excretion. Collection Conditions No restrictions. Repeat measurement inappropriate except in acute Frequency of testing presentation of undiagnosed suspected metabolic disorder. Version 1 Date: 25/01/11 Document agreed by: Dr NB Roberts . -
Laboratory Diagnostic Approaches in Metabolic Disorders
470 Review Article on Inborn Errors of Metabolism Page 1 of 14 Laboratory diagnostic approaches in metabolic disorders Ruben Bonilla Guerrero1, Denise Salazar2, Pranoot Tanpaiboon2,3 1Formerly Quest Diagnostics, Inc., Ruben Bonilla Guerrero, Rancho Santa Margarita, CA, USA; 2Quest Diagnostics, Inc., Denise Salazar and Pranoot Tanpaiboon, San Juan Capistrano, CA, USA; 3Genetics and Metabolism, Children’s National Rare Disease Institute, Washington, DC, USA Contributions: (I) Conception and design: All authors; (II) Administrative support: R Bonilla Guerrero; (III) Provision of study materials or patients: All authors; (IV) Collection and assembly of data: All authors; (V) Data analysis and interpretation: None; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. Correspondence to: Ruben Bonilla Guerrero. Formerly Quest Diagnostics, Inc., Ruben Bonilla Guerrero, 508 Sable, Rancho Santa Margarita, CA 92688, USA. Email: [email protected]. Abstract: The diagnosis of inborn errors of metabolism (IEM) takes many forms. Due to the implementation and advances in newborn screening (NBS), the diagnosis of many IEM has become relatively easy utilizing laboratory biomarkers. For the majority of IEM, early diagnosis prevents the onset of severe clinical symptoms, thus reducing morbidity and mortality. However, due to molecular, biochemical, and clinical variability of IEM, not all disorders included in NBS programs will be detected and diagnosed by screening alone. This article provides a general overview and simplified guidelines for the diagnosis of IEM in patients with and without an acute metabolic decompensation, with early or late onset of clinical symptoms. The proper use of routine laboratory results in the initial patient assessment is also discussed, which can help guide efficient ordering of specialized laboratory tests to confirm a potential diagnosis and initiate treatment as soon as possible.